Evaluation of a 2-aminoimidazole variant as adjuvant treatment for dermal bacterial infections

G Logan Draughn, C Leigh Allen, Patricia A Routh, Maria R Stone, Kelly R Kirker, Laura Boegli, Ryan M Schuchman, Keith E Linder, Ronald E Baynes, Garth James, Christian Melander, Angela Pollard, John Cavanagh

Research output: Contribution to journalArticle

5 Scopus citations
30 Downloads (Pure)

Abstract

2-Aminoimidazole (2-AI)-based compounds have been shown to efficiently disrupt biofilm formation, disperse existing biofilms, and resensitize numerous multidrug-resistant bacteria to antibiotics. Using Pseudomonas aeruginosa and Staphylococcus aureus, we provide initial pharmacological studies regarding the application of a 2-AI as a topical adjuvant for persistent dermal infections. In vitro assays indicated that the 2-AI H10 is nonbactericidal, resensitizes bacteria to antibiotics, does not harm the integument, and promotes wound healing. Furthermore, in vivo application of H10 on swine skin caused no gross abnormalities or immune reactions. Taken together, these results indicate that H10 represents a promising lead dermal adjuvant compound.
Original languageEnglish (US)
Pages (from-to)153-162
JournalDrug Design, Development and Therapy
Volume2017
Issue number11
StatePublished - Jan 11 2017

    Fingerprint

Keywords

  • transdermal absorption
  • antimicrobial activity
  • skin irritation
  • synergism
  • oroidin derivative
  • drip-flow reactor
  • ESKAPE pathogens

Cite this

Draughn, G. L., Allen, C. L., Routh, P. A., Stone, M. R., Kirker, K. R., Boegli, L., Schuchman, R. M., Linder, K. E., Baynes, R. E., James, G., Melander, C., Pollard, A., & Cavanagh, J. (2017). Evaluation of a 2-aminoimidazole variant as adjuvant treatment for dermal bacterial infections. Drug Design, Development and Therapy, 2017(11), 153-162.